Risk of PTLDs by all possible categories of 4 major PTLD risk factors
| No. of major PTLD risk factors* . | No. of patients . | No. of PTLDs . | RR† (95% CI) . | Cumulative incidence (%)‡ (95% CI) . | Time of last PTLD, y . |
|---|---|---|---|---|---|
| No risk factors | 21 686 | 29 | 1.0 (Reference) | 0.2 (0.1-0.4) | 12.2 |
| One risk factor | 3670 | 35 | 8.6 (5.3-14) | 1.1 (0.7-1.5) | 7.2 |
| Two risk factors | 1371 | 49 | 43 (27-69) | 3.6 (2.7-4.7) | 0.8 |
| Three or 4 risk factors | 174 | 14 | 110 (56-206) | 8.1 (4.6-12.7) | 0.7 |
| Total | 26 901 | 127 |
| No. of major PTLD risk factors* . | No. of patients . | No. of PTLDs . | RR† (95% CI) . | Cumulative incidence (%)‡ (95% CI) . | Time of last PTLD, y . |
|---|---|---|---|---|---|
| No risk factors | 21 686 | 29 | 1.0 (Reference) | 0.2 (0.1-0.4) | 12.2 |
| One risk factor | 3670 | 35 | 8.6 (5.3-14) | 1.1 (0.7-1.5) | 7.2 |
| Two risk factors | 1371 | 49 | 43 (27-69) | 3.6 (2.7-4.7) | 0.8 |
| Three or 4 risk factors | 174 | 14 | 110 (56-206) | 8.1 (4.6-12.7) | 0.7 |
| Total | 26 901 | 127 |
RR indicates relative risk; CI, confidence interval; ATG, antithymocyte globulin; and GVHD, graft-versus-host disease.
Four major PTLD risk factors are defined as follows: (1) selective T-cell depletion methods (see definitions in Table 3); (2) use of ATG therapy to prevent or treat acute graft-versus-host disease; (3) 2+ HLA antigen–mismatched siblings, or unrelated donors, accompanied by selective T-cell depletion methods or ATG therapy; (4) age 50 years or older at allogeneic HCT.
Risk of PTLDs relative to the patients with no major risk factors.
Cumulative incidence (calculated using competing risk methods) at the time of the last event (PTLD).